N/A N=590 Fatigue Management Programs for People With MS
Multiple Sclerosis
Primary: Change From Baseline in Fatigue Levels — 50.98; 56.88; 57.87 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Multiple Sclerosis · Internuclear Ophthalmoplegia · Fatigue
Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672
N/A N=181 Teleconference Fatigue Management for People With Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in Subscale Scores of the Fatigue Impact Scale — -3.74; -1.22; -4.24; -1.11 units on a scale — p=<0.05
Phase 3 N=8 ACTH for Fatigue in Multiple Sclerosis Patients
Multiple Sclerosis, Relapsing-Remitting
Primary: Fatigue at 28 Weeks — 56.50; 29.00; 55.00; 40.00 score on a scale
Phase 2 N=45 MitoQ for Fatigue in Multiple Sclerosis (MS)
Multiple Sclerosis · Fatigue
Primary: Modified Fatigue Inventory Scale (MFIS) — 46.5; 55.2; 54.3; 45.1 units on a scale — p=0.9489
N/A N=20 Telephone-Delivered Exercise for Multiple Sclerosis Fatigue
Multiple Sclerosis · Fatigue · Physical Activity
Primary: Daily Average Fatigue Intensity Score — 3.9; 4.4; 3.2; 2.3 units on a scale
N/A N=35 Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Change in Average Fatigue Severity Scale (FSS) Score — 45.824; 46.714 score on a scale
Phase 3 N=141 Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Fatigue in Multiple Sclerosis
Primary: Modified Fatigue Impact Scale (MFIS) Score — 40.6; 41.3; 39.0; 38.6 score on a scale
N/A N=34 Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Parkinson's Disease · Multiple Sclerosis
Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L
Phase 4 N=336 Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
Multiple Sclerosis
Primary: Change in the Modified Fatigue Impact Scale (MFIS) Score — -15.2; -16.0; -17.3 score on a scale — p=0.3451
Phase 2 N=18 Ketamine for Treatment of MS Fatigue
Multiple Sclerosis · Fatigue
Primary: Change in Daily Fatigue Severity Score — -0.05; -0.05 score on a scale
N/A N=21 Prospective Case Series to Refine Standalone Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue
Multiple Sclerosis · Fatigue
Primary: Intervention Acceptability — 4.36; 4.64; 4.68 Units on a scale
Phase 2 N=15 A Study of Oxidative Pathways in MS Fatigue
Progressive Multiple Sclerosis · Fatigue
Primary: Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine. — 12; 6 adverse events
N/A N=64 Telehealth-Based Exercise Program to Treat Fatigue in MS
Multiple Sclerosis
Primary: Fatigue — 53.78; 49.65; 45.76; 50.53 units on a scale — p=.013
Phase 4 N=36 A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Multiple Sclerosis · Fatigue · Insomnia
Primary: Change in Insomnia Severity Index (ISI) Score — -4; -2 score on a scale
Phase 3 N=33 Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Learning and Memory Measures. — -3.38; -.07; -1.38; 1.93 Items recalled — p== .19
Phase 2 N=56 American Ginseng Treatment for Multiple Sclerosis Related Fatigue
Multiple Sclerosis
Primary: Fatigue Severity Scale — 5.5; 5.5 units on a scale
Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
N/A N=14 Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?
Multiple Sclerosis
Primary: Leg Muscle Strength With and Without tDCS. — 323; 330 Newtons
N/A N=6 tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis
Multiple Sclerosis
Primary: Neuropathic Pain Questionnaire (NPQ) Contains 12 Items. — 21.3; 10.3 Points
Phase 4 N=26 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
N/A N=20 Mechanisms to Reduce Mental and Physical Fatigue Following Exercise Training in Older Adults
Fatigue · Aging
Primary: Fatigue — -5.6; -4.1 change in fatigue severity score
Phase 2 N=121 Stress Management for Patients With Multiple Sclerosis
Multiple Sclerosis
Primary: No.of Gd+ Lesions From Week 8 to Week 24 — 46; 33; 5; 13 participants — p=0.04
Phase 2 N=262 Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score — -1.5; -1.8; -1.9 units on a scale
N/A N=12 Post-stroke Fatigue, Inflammation, tDCS
Stroke · Fatigue · Chronic Stroke
Primary: Change in Fatigue Severity Scale (FSS) Score — -0.4; 0.2 units on a scale
Phase 2 N=12 A Rehabilitation Therapy for Post-stroke Fatigue
Stroke
Primary: Feasibility of Recruitment Process — 120; 49; 20; 12 participants
N/A N=45 Carnosine Loading and Periodized Training in MS and HC
Multiple Sclerosis · Exercise Therapy · Dietary Supplement
Primary: VO2max — 40.4; 41.2; 44; 43.4 ml/kg/min
N/A N=74 Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue
Post Covid-19 Patients
Primary: Fatigue Assessment Scale (FAS) — 31.32; 28.42; 14.90; 15.3 Total score (1 to 5 point scale)
Early Phase 1 N=12 Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis
Fatigue · Overheating
Primary: Change in Time to Exhaustion — 568; 552 seconds
Phase 4 N=12 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS
Chronic Fatigue Syndrome
Primary: Change in Fatigue Impact Scale at 6 Weeks — -32.6; -1.5 units on a scale — p=< 0.05